Company News
Guggenheim Names Celldex Top Biotech Pick
Guggenheim Securities reaffirmed Celldex Therapeutics as its top biotechnology pick, maintaining a Buy rating and $100 price target.
The firm projects barzolvolimab could achieve $3 billion peak globa
